253 results on '"Persing DH"'
Search Results
2. Evaluation of immunologic and immunogenetic factors in Whippel's disease
- Author
-
Cleavinger, PJ, primary, Abdelmalek, MF, additional, Homburger, HA, additional, and Persing, DH, additional
- Published
- 1998
- Full Text
- View/download PDF
3. Lack of association of sarcoidosis and intestinal lymphoma with T. Whippelii infection
- Author
-
Abdelmalek, MF, primary, Procop, GW, additional, Mitchell, PS, additional, and Persing, DH, additional
- Published
- 1998
- Full Text
- View/download PDF
4. Association of hepatitis C virus in cerebrospinal fluid with cryoglobulinemia and a syndrome of cerebritis
- Author
-
Perez, RG, primary, Duffy, J, additional, Petty, GW, additional, Germer, JJ, additional, Rys, P, additional, Gross, JB, additional, and Persing, DH, additional
- Published
- 1998
- Full Text
- View/download PDF
5. Role of hepatitis G in symptomatic cryoglobulinemia
- Author
-
Perez, RG, primary, Gross, JB, additional, Duffy, J, additional, and Persing, DH, additional
- Published
- 1998
- Full Text
- View/download PDF
6. Hepatitis B virus (HBV) precore sequences in African patients with hepatocellular carcinoma
- Author
-
Laskus, T., primary, Rakela, J., additional, Nowicki, M., additional, Adjukiewicz, A., additional, Mosley, J.W., additional, and Persing, DH, additional
- Published
- 1995
- Full Text
- View/download PDF
7. Blood donors who are repeatedly reactive for hepatitis C virus on enzyme immunoassay and positive on recombinant immunoblot assay: evidence of failure to identify some risk factors
- Author
-
Moore, SB, primary, Kruger, JR, additional, Rakela, J, additional, Vamvakas, EC, additional, Schimek, C, additional, Germer, JJ, additional, and Persing, DH, additional
- Published
- 1995
- Full Text
- View/download PDF
8. Hepatocellular carcinoma in patients infected with different hepatitis C genotypes
- Author
-
Zein, NN, primary, Poterucha, JJ, additional, Wiesner, RH, additional, Gross, JB, additional, Gossard, AA, additional, Wendt, NK, additional, Mitchell, PS, additional, Germer, JJ, additional, and Persing, DH, additional
- Published
- 1995
- Full Text
- View/download PDF
9. How to recognize and treat tick-borne infections.
- Author
-
Kalish R, Persing DH, Segreti J, and Walker DH
- Abstract
Tick-borne illnesses are maddeningly nonspecific in their presentation, and the tick bite itself often goes unnoticed. If you ask the right questions and perform a few timely tests, you'll improve your confidence--and the outcome for your patients. [ABSTRACT FROM AUTHOR]
- Published
- 1997
10. Nucleic acid-based pathogen discovery techniques: Potential application to xenozoonoses
- Author
-
Persing, DH
- Abstract
Pathogen discovery techniques based on detection and characterization of microbial nucleic acids have potential application to the field of xenotransplantation. Techniques such as broad-range polymerase chain reaction and representational difference analysis may make it possible to define the zoonotic flora present within donor animal species to an extent never before possible. This review describes the current practice of these techniques, with an emphasis on the use of these methods for identifying zoonotic agents. Identification of potential pathogens in colony-reared donors may lead to isolation and selective breeding practices that could ultimately eliminate these agents from the donor pool. (Mol Diagn 1996 Sep;1(3):243-254)
- Published
- 1996
- Full Text
- View/download PDF
11. Maintaining point of care testing capacity and pandemic preparedness in the post-COVID-19 era.
- Author
-
Rakeman-Cagno JL, Persing DH, and Loeffelholz MJ
- Subjects
- Humans, SARS-CoV-2, COVID-19 Testing, Pandemics, Pandemic Preparedness, Point-of-Care Testing, COVID-19 diagnosis, COVID-19 epidemiology
- Abstract
Introduction: Testing at the point of care (we also refer to the 'point of need'), with rapid, actionable results reported to the patient and provider within hours can impact the individual as well as public health. Faster testing is good for patients and public health outcomes during 'peace time' (outside of the pandemic setting)., Areas Covered: Testing at the point of need was important during the COVID-19 pandemic to meet testing capacity demands, providing actionable results, and for providing testing within communities to increase access for all populations. Resources were acquired and built up dramatically during the pandemic as part of the response. With the end of the COVID-19 public health emergency and transition back to 'peace time' some testing sites have successfully shifted to using this capacity for testing for other critical needs, like sexually transmitted infection (STI) testing, and response to other seasonal diseases and for outbreak response., Expert Opinion: The increased testing capacity added to handle unprecedented testing volume during the COVID-19 pandemic can be repurposed for other critical infectious diseases during 'peace time' (post-COVID-19 pandemic). This maintains testing capacity for the next pandemic.
- Published
- 2024
- Full Text
- View/download PDF
12. Rapid Detection of Extensive Drug Resistance by Xpert MTB/XDR Optimizes Therapeutic Decision-Making in Rifampin-Resistant Tuberculosis Patients.
- Author
-
Chen X, Li R, Ge S, Li Y, Cai C, Weng T, Zhang Y, Jiang J, Feng Z, Chen Y, Zhang Y, Ma J, Persing DH, Chen J, Tang YW, Sun F, and Zhang W
- Subjects
- Humans, Rifampin pharmacology, Rifampin therapeutic use, Sensitivity and Specificity, Fluoroquinolones pharmacology, Fluoroquinolones therapeutic use, Drug Resistance, Bacterial, Sputum microbiology, Antibiotics, Antitubercular pharmacology, Tuberculosis diagnosis, Mycobacterium tuberculosis genetics, Tuberculosis, Multidrug-Resistant diagnosis, Tuberculosis, Multidrug-Resistant drug therapy, Tuberculosis, Multidrug-Resistant microbiology
- Abstract
The Xpert MTB/XDR assay met the critical need for etiologic diagnosis of tuberculosis and rifampin resistance in previous studies. However, its benefits in tailoring the treatment regimen and improving the outcome for patients with rifampin-resistant tuberculosis (RR-TB) require further investigation. In this study, the Xpert MTB/XDR assay was used to determine the resistance profile of second-line drugs for RR-TB patients in two registered multicenter clinical trials, TB-TRUST (NCT03867136) and TB-TRUST-plus (NCT04717908), with the aim of testing the efficacy of all-oral shorter regimens in RR-TB patients in China. Patients would receive the fluoroquinolone-based all-oral shorter regimen, the injectable-containing regimen, or the bedaquiline-based regimen depending on fluoroquinolone susceptibility by using Xpert MTB/XDR. Among the 497 patients performed with Xpert MTB/XDR, 128 (25.8%) had infections resistant to fluoroquinolones and/or second-line injectable drugs (SLIDs). A total of 371 participants were recruited for the trials, and whole-genome sequencing (WGS) was performed on all corresponding culture-positive baseline strains. Taking the WGS results as the standard, the accuracy of the Xpert MTB/XDR assay in terms of resistance detection was 95.2% to 99.0% for all drugs. A total of 33 cases had inconsistent results, 9 of which were due to resistance heterogeneity. Most of the patients (241/281, 85.8%) had sputum culture conversion at 2 months. In conclusion, the Xpert MTB/XDR assay has the potential to serve as a quick reflex test in patients with RR-TB, as detected via Xpert MTB/RIF, to provide a reliable drug susceptibility profile of the infecting Mycobacterium tuberculosis strain and to initiate optimized treatment promptly., Competing Interests: The authors declare no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
13. Novel Host Response-Based Diagnostics to Differentiate the Etiology of Fever in Patients Presenting to the Emergency Department.
- Author
-
Atallah J, Ghebremichael M, Timmer KD, Warren HM, Mallinger E, Wallace E, Strouts FR, Persing DH, and Mansour MK
- Abstract
Fever is a common presentation to urgent-care services and is linked to multiple disease processes. To rapidly determine the etiology of fever, improved diagnostic modalities are necessary. This prospective study of 100 hospitalized febrile patients included both positive (FP) and negative (FN) subjects in terms of infection status and 22 healthy controls (HC). We evaluated the performance of a novel PCR-based assay measuring five host mRNA transcripts directly from whole blood to differentiate infectious versus non-infectious febrile syndromes as compared to traditional pathogen-based microbiology results. The FP and FN groups observed a robust network structure with a significant correlation between the five genes. There were statistically significant associations between positive infection status and four of the five genes: IRF-9 (OR = 1.750, 95% CI = 1.16-2.638), ITGAM (OR = 1.533, 95% CI = 1.047-2.244), PSTPIP2 (OR = 2.191, 95% CI = 1.293-3.711), and RUNX1 (OR = 1.974, 95% CI = 1.069-3.646). We developed a classifier model to classify study participants based on these five genes and other variables of interest to assess the discriminatory power of the genes. The classifier model correctly classified more than 80% of the participants into their respective groups, i.e., FP or FN. The GeneXpert prototype holds promise for guiding rapid clinical decision-making, reducing healthcare costs, and improving outcomes in undifferentiated febrile patients presenting for urgent evaluation.
- Published
- 2023
- Full Text
- View/download PDF
14. Forty Years of Molecular Diagnostics for Infectious Diseases.
- Author
-
Schmitz JE, Stratton CW, Persing DH, and Tang YW
- Subjects
- Humans, Pathology, Molecular, Nucleic Acid Amplification Techniques methods, Molecular Diagnostic Techniques methods, COVID-19 diagnosis, Communicable Diseases diagnosis, Nucleic Acids
- Abstract
Nearly 40 years have elapsed since the invention of the PCR, with its extremely sensitive and specific ability to detect nucleic acids via in vitro enzyme-mediated amplification. In turn, more than 2 years have passed since the onset of the coronavirus disease 2019 (COVID-19) pandemic, during which time molecular diagnostics for infectious diseases have assumed a larger global role than ever before. In this context, we review broadly the progression of molecular techniques in clinical microbiology, to their current prominence. Notably, these methods now entail both the detection and quantification of microbial nucleic acids, along with their sequence-based characterization. Overall, we seek to provide a combined perspective on the techniques themselves, as well as how they have come to shape health care at the intersection of technologic innovation, pathophysiologic knowledge, clinical/laboratory logistics, and even financial/regulatory factors.
- Published
- 2022
- Full Text
- View/download PDF
15. A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.
- Author
-
Verma R, Patil S, Zhang N, Moreira FMF, Vitorio MT, Santos ADS, Wallace E, Gnanashanmugam D, Persing DH, Savic RM, Croda J, and Andrews JR
- Subjects
- Algorithms, Antitubercular Agents administration & dosage, Cohort Studies, Genotype, Humans, Isoniazid administration & dosage, Multiplex Polymerase Chain Reaction, Pharmacogenetics, Predictive Value of Tests, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary metabolism, Antitubercular Agents pharmacokinetics, Arylamine N-Acetyltransferase genetics, Isoniazid pharmacokinetics, Pharmacogenomic Testing, Polymorphism, Genetic genetics, Tuberculosis, Pulmonary genetics
- Abstract
Rationale: Standardized dosing of antitubercular drugs contributes to a substantial incidence of toxicities, inadequate treatment response, and relapse, in part due to variable drug concentrations achieved. SNPs in the NAT2 ( N -acetyltransferase-2) gene explain the majority of interindividual pharmacokinetic variability of isoniazid (INH). However, an obstacle to implementing pharmacogenomic-guided dosing is the lack of a point-of-care assay. Objectives: To develop and test a NAT2 classification algorithm, validate its performance in predicting isoniazid clearance, and develop a prototype pharmacogenomic assay. Methods: We trained random forest models to predict NAT2 acetylation genotype from unphased SNP data using a global collection of 8,561 phased genomes. We enrolled 48 patients with pulmonary tuberculosis, performed sparse pharmacokinetic sampling, and tested the acetylator prediction algorithm accuracy against estimated INH clearance. We then developed a cartridge-based multiplex quantitative PCR assay on the GeneXpert platform and assessed its analytical sensitivity on whole blood samples from healthy individuals. Measurements and Main Results: With a 5-SNP model trained on two-thirds of the data ( n = 5,738), out-of-sample acetylation genotype prediction accuracy on the remaining third ( n = 2,823) was 100%. Among the 48 patients with tuberculosis, predicted acetylator types were 27 (56.2%) slow, 16 (33.3%) intermediate, and 5 (10.4%) rapid. INH clearance rates were lowest in predicted slow acetylators (median 14.5 L/h), moderate in intermediate acetylators (median 40.3 L/h), and highest in fast acetylators (median 53.0 L/h). The cartridge-based assay accurately detected all allele patterns directly from 25 μl of whole blood. Conclusions: An automated pharmacogenomic assay on a platform widely used globally for tuberculosis diagnosis could enable personalized dosing of INH.
- Published
- 2021
- Full Text
- View/download PDF
16. Real-time Screening of Specimen Pools for Coronavirus Disease 2019 (COVID-19) Infection at Sanya Airport, Hainan Island, China.
- Author
-
Li H, Sun K, Persing DH, Tang YW, and Shen D
- Subjects
- Airports, China epidemiology, Contact Tracing, Humans, Mass Screening, SARS-CoV-2, COVID-19
- Abstract
A 10:1 pooled test strategy on-site at an airport of China was pursued, resulting in increased test throughput, limited use of reagents, and increased testing efficiency without loss of sensitivity. This testing approach has the potential to reduce the need for contact tracing when the results are delivered first time., (© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
17. A novel blood-based assay for treatment monitoring of tuberculosis.
- Author
-
Zimmer AJ, Schumacher SG, Södersten E, Mantsoki A, Wyss R, Persing DH, Banderby S, Strömqvist Meuzelaar L, Prieto J, Gnanashanmugam D, Khatri P, Ongarello S, Ruhwald M, and Denkinger CM
- Subjects
- Diagnostic Tests, Routine, Humans, Prospective Studies, Mycobacterium tuberculosis genetics, Tuberculosis diagnosis, Tuberculosis drug therapy, Tuberculosis, Pulmonary diagnosis, Tuberculosis, Pulmonary drug therapy, Tuberculosis, Pulmonary genetics
- Abstract
Objectives: A novel 3-gene host transcriptional signature (GBP5, DUSP3 and KLF2) has been validated for tuberculosis (TB) treatment monitoring using laboratory-based RNA sequencing platforms. The signature was recently translated by Cepheid into a prototype cartridge-based test that can be run on the GeneXpert instrument. In this study, we prospectively evaluated the change in the expression of the cartridge-based 3-gene signature following treatment initiation among pulmonary TB patients who were microbiologically cured at the end of treatment., Results: The 3-gene signature expression level (TB score) changed significantly over time with respect to baseline among 31 pulmonary TB patients. The greatest increase in TB score occurred within the first month of treatment (median fold-increase in TB score: 1.08 [IQR 0.54-1.52]) and plateaued after 4 months of treatment (median TB score: 1.97 [IQR: 1.03-2.33]). The rapid and substantial increase of the TB score in the first month of treatment holds promise for the early identification of patients that respond to TB treatment. The plateau in TB score at 4 months may indicate early clearance of disease and could direct treatment to be shortened. These hypotheses need to be further explored with larger prospective treatment monitoring studies.
- Published
- 2021
- Full Text
- View/download PDF
18. Blood-based host biomarker diagnostics in active case finding for pulmonary tuberculosis: A diagnostic case-control study.
- Author
-
Moreira FMF, Verma R, Pereira Dos Santos PC, Leite A, da Silva Santos A, de Araujo RCP, da Silva BO, de Sá Queiroz JHF, Persing DH, Södersten E, Gnanashanmugam D, Khatri P, Croda J, and Andrews JR
- Abstract
Background: There is a need to identify scalable tuberculosis screening strategies among high burden populations. The WHO has identified a non-sputum-based triage test as a development priority., Methods: We performed a diagnostic case-control study of point-of-care C-reactive protein (CRP) and Prototype-Xpert-MTB-Host-Response (Xpert-MTB-HR) assays in the context of a mass screening program for tuberculosis in two prisons in Brazil. All incarcerated individuals irrespective of symptoms were screened by sputum Xpert MTB/RIF and sputum culture. Among consecutive, Xpert MTB/RIF or culture-confirmed cases and Xpert MTB/RIF and culture-negative controls, CRP was quantified in serum by a point-of-care assay (iChroma-II) and a 3-gene expression score was quantified from whole blood using the Xpert-MTB-HR cartridge. We evaluated receiver operating characteristic area under the curve (AUC) and assessed specificity at 90% sensitivity and sensitivity at 70% specificity, consistent with WHO target product profile (TPP) benchmarks., Findings: Two hundred controls (no TB) and 100 culture- or Xpert MTB/RIF-positive tuberculosis cases were included. Half of tuberculosis cases and 11% of controls reported any tuberculosis symptoms. AUC for CRP was 0·79 (95% CI: 0·73-0·84) and for Xpert-MTB-HR was 0·84 (95% CI: 0·79-0·89). At 90% sensitivity, Xpert-MTB-HR had significantly higher specificity (53·0%, 95% CI: 45·0-69·0%) than CRP (28·1%, 95% CI: 20·2-41·8%) ( p = 0·003), both well below the TPP benchmark of 70%. Among individuals with medium or high sputum Xpert MTB/RIF semi-quantitative load, sensitivity (at 70% specificity) of CRP (90·3%, 95% CI: 74·2-98·0) and Xpert-MTB-HR (96·8%, 95% CI: 83·3-99·9%) was higher., Interpretation: For active case finding in this high tuberculosis-burden setting, CRP and Xpert-MTB-HR did not meet TPP benchmarks for a triage test. However, Xpert-MTB-HR was highly sensitive in detecting individuals with medium or high sputum bacillary burden., Funding: National Institutes of Health (R01 AI130058 and R01 AI149620) and Brazilian National Council for Scientific and Technological Development (CNPq-404182/2019-4)., Competing Interests: JRA received grants from the U.S. National Institutes of Health to support this research. PK is a co-inventor on a 3-gene TB score pending patent owned by Stanford University, which has been licensed for commercialization. PK is a consultant with Cepheid. DHP, ES, and DG are employed by Cepheid. Xpert-MTB-HR cartridges were provided by Cepheid. Cepheid had no role in selection of participants, assay performance and interpretation, or data analysis, and did not have access to the study results until all analyses were completed., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
19. Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV Test.
- Author
-
Mostafa HH, Carroll KC, Hicken R, Berry GJ, Manji R, Smith E, Rakeman JL, Fowler RC, Leelawong M, Butler-Wu SM, Quintero D, Umali-Wilcox M, Kwiatkowski RW, Persing DH, Weir F, and Loeffelholz MJ
- Subjects
- Humans, Nasopharynx, SARS-CoV-2, Sensitivity and Specificity, COVID-19 diagnosis, Influenza, Human diagnosis, Molecular Diagnostic Techniques methods
- Abstract
With the approach of respiratory virus season in the Northern Hemisphere, clinical microbiology and public health laboratories will need rapid diagnostic assays to distinguish severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from influenza virus and respiratory syncytial virus (RSV) infections for diagnosis and surveillance. In this study, the clinical performance of the Xpert Xpress SARS-CoV-2/Flu/RSV test (Cepheid, Sunnyvale, CA, USA) for nasopharyngeal swab specimens was evaluated in four centers: Johns Hopkins Medical Microbiology Laboratory, Northwell Health Laboratories, NYC Public Health Laboratory, and Los Angeles County/University of Southern California (LAC+USC) Medical Center. A total of 319 nasopharyngeal swab specimens, positive for SARS-CoV-2 ( n = 75), influenza A virus ( n = 65), influenza B virus ( n = 50), or RSV ( n = 38) or negative ( n = 91) by the standard-of-care nucleic acid amplification tests at each site, were tested using the Cepheid panel test. The overall positive percent agreement for the SARS-CoV-2 target was 98.7% ( n = 74/75), and the negative agreement was 100% ( n = 91), with all other analytes showing 100% total agreement ( n = 153). Standard-of-care tests to which the Cepheid panel was compared included the Cepheid Xpert Xpress SARS-CoV-2, Cepheid Xpert Xpress Flu/RSV, GenMark ePlex respiratory panel, BioFire respiratory panel 2.1 and v1.7, DiaSorin Simplexa COVID-19 Direct, and Hologic Panther Fusion SARS-CoV-2 assays. The Xpert Xpress SARS-CoV-2/Flu/RSV test showed high sensitivity and accuracy for all analytes included in the test. This test will provide a valuable clinical diagnostic and public health solution for detecting and differentiating SARS-CoV-2, influenza A and B virus, and RSV infections during the current respiratory virus season., (Copyright © 2021 Mostafa et al.)
- Published
- 2021
- Full Text
- View/download PDF
20. Diagnostic Accuracy Study of a Novel Blood-Based Assay for Identification of Tuberculosis in People Living with HIV.
- Author
-
Södersten E, Ongarello S, Mantsoki A, Wyss R, Persing DH, Banderby S, Strömqvist Meuzelaar L, Prieto J, Gnanashanmugam D, Khatri P, Schumacher SG, and Denkinger CM
- Subjects
- Diagnostic Tests, Routine, Humans, Rifampin, Sensitivity and Specificity, Sputum, HIV Infections complications, Mycobacterium tuberculosis, Tuberculosis diagnosis, Tuberculosis, Pulmonary
- Abstract
A nonsputum triage test to rule out tuberculosis (TB) disease is a WHO high-priority diagnostic, and a combinatory score based on a 3-gene host signature has shown promise in discriminating TB from other illnesses. We evaluated the accuracy of an early-prototype cartridge assay ("Xpert MTB Host Response" or Xpert-MTB-HR-Prototype) of this 3-gene signature on biobanked blood samples from people living with HIV (PLHIV) against a comprehensive microbiological reference standard (CMRS) and against Xpert MTB/RIF on the first sputum sample alone. We depict results based on performance targets set by the WHO in comparison with a laboratory-based C-reactive protein (CRP) assay. Of 201 patients included, 67 were culture positive for Mycobacterium tuberculosis The areas under the concentration-time curve (AUCs) for Xpert-MTB-HR-Prototype were 0.89 (confidence interval [CI], 0.83 to 0.94) against the CMRS and 0.94 (CI, 0.89 to 0.98) against Xpert MTB/RIF. Considering Xpert-MTB-HR-Prototype as a triage test (at the nearest upper value of sensitivity to 90%), specificities were 55.8% (CI, 47.2 to 64.1%) compared to the CMRS and 85.9% (CI, 79.3 to 90.7%) compared to Xpert MTB/RIF as confirmatory tests. Considering Xpert-MTB-HR-Prototype as a stand-alone diagnostic test, at a specificity near 95%, the test achieved a sensitivity of 65.7% (CI, 53.7 to 75.9%), while the CRP assay achieved a sensitivity of only 13.6% (CI, 7.3 to 23.4%). In this first accuracy study of a prototype blood-based host marker assay, we show the possible value of the assay for triage and diagnosis in PLHIV., (Copyright © 2021 Södersten et al.)
- Published
- 2021
- Full Text
- View/download PDF
21. The Xpert MTB/RIF Ultra assay detects Mycobacterium tuberculosis complex DNA in white rhinoceros (Ceratotherium simum) and African elephants (Loxodonta africana).
- Author
-
Goosen WJ, Kerr TJ, Kleynhans L, Warren RM, van Helden PD, Persing DH, Parsons SDC, Buss P, and Miller MA
- Subjects
- Animals, Antibiotics, Antitubercular pharmacology, Biological Assay, Bronchoalveolar Lavage Fluid, Diagnostic Tests, Routine veterinary, Humans, Limit of Detection, Mycobacterium bovis, Mycobacterium tuberculosis genetics, Reproducibility of Results, Rifampin pharmacology, Sensitivity and Specificity, Sputum microbiology, DNA, Bacterial isolation & purification, Elephants microbiology, Mycobacterium tuberculosis isolation & purification, Perissodactyla microbiology
- Abstract
The study describes the novel use of the Xpert MTB/RIF Ultra assay for detection of Mycobacterium tuberculosis complex (MTBC) DNA in samples from white rhinoceros (Ceratotherium simum) and African elephants (Loxodonta africana). Culture negative respiratory sample matrices were spiked to determine if the Ultra could detect MTBC DNA in rhinoceros and elephant samples. Rhinoceros bronchial alveolar lavage fluid (BALF) was found to have an inhibitory effect on the Ultra. In this study, the limit of detection (LOD) of M. tuberculosis H37Rv in all spiked animal samples were 2 CFU/ml compared to 15.6 CFU/ml for humans, while the LOD for M. bovis SB0121 was 30 CFU/ml compared to 143.4 CFU/ml for M. bovis BCG in humans. Screening was performed on stored tissue and respiratory samples from known MTBC-infected animals and MTBC DNA was detected in 92% of samples collected from six rhinoceros and two elephants. Conversely, 83% of culture-negative tissue and respiratory samples from uninfected animals tested negative on the Ultra. In conclusion, the Ultra assay appears to be a sensitive and rapid diagnostic test for the detection of MTBC DNA from tissue and respiratory samples collected from African elephants and rhinoceros. Furthermore, the Ultra assay could provide a new tool for the detection of MTBC in various sample types from other wildlife species.
- Published
- 2020
- Full Text
- View/download PDF
22. Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test.
- Author
-
Loeffelholz MJ, Alland D, Butler-Wu SM, Pandey U, Perno CF, Nava A, Carroll KC, Mostafa H, Davies E, McEwan A, Rakeman JL, Fowler RC, Pawlotsky JM, Fourati S, Banik S, Banada PP, Swaminathan S, Chakravorty S, Kwiatkowski RW, Chu VC, Kop J, Gaur R, Sin MLY, Nguyen D, Singh S, Zhang N, and Persing DH
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Automation, Laboratory methods, Betacoronavirus genetics, COVID-19, COVID-19 Testing, Child, Child, Preschool, Coronavirus Infections virology, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Nasopharynx virology, Pandemics, Pneumonia, Viral virology, SARS-CoV-2, Sensitivity and Specificity, Young Adult, Betacoronavirus isolation & purification, Clinical Laboratory Techniques methods, Coronavirus Infections diagnosis, Molecular Diagnostic Techniques methods, Pneumonia, Viral diagnosis
- Abstract
Nucleic acid amplification tests (NAATs) are the primary means of identifying acute infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Accurate and fast test results may permit more efficient use of protective and isolation resources and allow rapid therapeutic interventions. We evaluated the analytical and clinical performance characteristics of the Xpert Xpress SARS-CoV-2 (Xpert) test, a rapid, automated molecular test for SARS-CoV-2. Analytical sensitivity and specificity/interference were assessed with infectious SARS-CoV-2; other infectious coronavirus species, including SARS-CoV; and 85 nasopharyngeal swab specimens positive for other respiratory viruses, including endemic human coronaviruses (hCoVs). Clinical performance was assessed using 483 remnant upper- and lower-respiratory-tract specimens previously analyzed by standard-of-care (SOC) NAATs. The limit of detection of the Xpert test was 0.01 PFU/ml. Other hCoVs, including Middle East respiratory syndrome coronavirus, were not detected by the Xpert test. SARS-CoV, a closely related species in the subgenus Sarbecovirus , was detected by a broad-range target (E) but was distinguished from SARS-CoV-2 (SARS-CoV-2-specific N2 target). Compared to SOC NAATs, the positive agreement of the Xpert test was 219/220 (99.5%), and the negative agreement was 250/261 (95.8%). A third tie-breaker NAAT resolved all but three of the discordant results in favor the Xpert test. The Xpert test provided sensitive and accurate detection of SARS-CoV-2 in a variety of upper- and lower-respiratory-tract specimens. The high sensitivity and short time to results of approximately 45 min may impact patient management., (Copyright © 2020 American Society for Microbiology.)
- Published
- 2020
- Full Text
- View/download PDF
23. Laboratory Diagnosis of COVID-19: Current Issues and Challenges.
- Author
-
Tang YW, Schmitz JE, Persing DH, and Stratton CW
- Subjects
- COVID-19, COVID-19 Testing, COVID-19 Vaccines, Humans, Pandemics, Polymerase Chain Reaction, SARS-CoV-2, Betacoronavirus genetics, Betacoronavirus immunology, Betacoronavirus isolation & purification, Clinical Laboratory Techniques, Coronavirus Infections diagnosis, Pneumonia, Viral diagnosis
- Abstract
The COVID-19 outbreak has had a major impact on clinical microbiology laboratories in the past several months. This commentary covers current issues and challenges for the laboratory diagnosis of infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In the preanalytical stage, collecting the proper respiratory tract specimen at the right time from the right anatomic site is essential for a prompt and accurate molecular diagnosis of COVID-19. Appropriate measures are required to keep laboratory staff safe while producing reliable test results. In the analytic stage, real-time reverse transcription-PCR (RT-PCR) assays remain the molecular test of choice for the etiologic diagnosis of SARS-CoV-2 infection while antibody-based techniques are being introduced as supplemental tools. In the postanalytical stage, testing results should be carefully interpreted using both molecular and serological findings. Finally, random-access, integrated devices available at the point of care with scalable capacities will facilitate the rapid and accurate diagnosis and monitoring of SARS-CoV-2 infections and greatly assist in the control of this outbreak., (Copyright © 2020 Tang et al.)
- Published
- 2020
- Full Text
- View/download PDF
24. mRNA Detection in Anal Cytology: A Feasible Approach for Anal Cancer Screening in Men Who Have Sex with Men Living With HIV.
- Author
-
Del Pino M, Martí C, Gaber J, Svanholm-Barrie C, Rodríguez-Carunchio L, Rodriguez-Trujillo A, Carreras N, Fuertes I, Barnadas E, Marimón L, Blanco JL, Persing DH, Torné A, and Ordi J
- Abstract
There is growing interest in anal cancer screening strategies. However, cytological/molecular evaluation of anal samples is challenging. We aimed to determine the feasibility of detecting, in anal liquid-based cytologies, the expression of biomarkers involved in the cell cycle disturbance elicited by human papillomavirus (HPV). The accuracy of this approach in the identification of high-grade squamous intraepithelial lesions/anal intraepithelial neoplasia grade2-3 (HSIL/AIN2-3) was also evaluated. 215 anal cytologies from men having sex with men living with human immunodeficiency virus were evaluated. Patients showing concordant cytological and anoscopy-directed biopsy diagnosis were selected: 70 with negative cytology and HPV test, 70 with low-grade SIL (LSIL/AIN1) cytology and biopsy, and 75 with cytology and biopsy of HSIL/AIN2-3. CDKN2A/p16, MKI67 and TOP2A mRNA expression was analyzed. HPV detection was performed with Xpert HPV Assay (Cepheid, Sunnyvale, CA, USA). HSIL/AIN2-3 showed higher expression for the biomarkers than LSIL/AIN1 or negative samples. The specificity for HSIL/AIN2-3 detection for a sensitivity established at 70% was 44.7% (95%confidence interval [CI] 36.5-53.2) for TOP2A and MKI67 and 54.5% (95%CI 46.0-62.8%) for CDKN2A/p16. mRNA detection of cell biomarkers in anal liquid-based cytology is feasible. Further studies are warranted to confirm if strategies based on mRNA detection have any role in anal cancer screening., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2019
- Full Text
- View/download PDF
25. Guidelines Support the Value of Stand-Alone Nucleic Acid Amplification Tests for Clostridioides ( Clostridium ) difficile Infection.
- Author
-
Tenover FC, Persing DH, and Fang F
- Subjects
- Humans, Nucleic Acid Amplification Techniques, Clostridioides difficile genetics, Clostridium Infections, Enterocolitis, Pseudomembranous
- Published
- 2019
- Full Text
- View/download PDF
26. Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay.
- Author
-
Lamoury FMJ, Bajis S, Hajarizadeh B, Marshall AD, Martinello M, Ivanova E, Catlett B, Mowat Y, Marks P, Amin J, Smith J, Ezard N, Cock V, Hayllar J, Persing DH, Kleman M, Cunningham P, Dore GJ, Applegate TL, and Grebely J
- Subjects
- Adult, Australia, Blood Specimen Collection methods, Cohort Studies, Female, Humans, Male, Middle Aged, Point-of-Care Systems, Point-of-Care Testing, RNA, Viral genetics, Sensitivity and Specificity, Serologic Tests methods, Biological Assay methods, Hepacivirus genetics, Hepatitis C virology, Viral Load methods
- Abstract
Point-of-care hepatitis C virus (HCV) RNA testing is advantageous, enabling diagnosis of active infection in a single visit. This study evaluated the sensitivity and specificity of the Xpert HCV Viral Load Finger-Stick assay (Xpert HCV VL FS) for HCV RNA detection (finger-stick) and the Xpert HCV Viral Load assay (plasma) compared with the Abbott RealTime HCV Viral Load assay by venepuncture. Plasma and finger-stick capillary whole-blood samples were collected from participants in an observational cohort in Australia. Of 223 participants enrolled, HCV RNA was detected in 40% of participants (85 of 210) with available Xpert HCV Viral Load testing. Participants receiving HCV therapy were excluded from subsequent analyses (n = 16). Sensitivity of the Xpert HCV Viral Load assay for HCV RNA quantification in plasma collected by venepuncture was 100.0% (95% confidence interval [CI] 96.9%-100.0%) and specificity was 100.0% (95% CI, 94.4%-100.0%). Sensitivity of the Xpert HCV VL FS assay for HCV RNA quantification in samples collected by finger-stick was 100.0% (95% CI, 93.9%-100.0%) and specificity was 100.0% (95% CI, 96.6%-100.0%). The Xpert HCV VL FS test can accurately detect active infection from a finger-stick sample in 1 hour allowing single-visit HCV diagnosis.
- Published
- 2018
- Full Text
- View/download PDF
27. Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States.
- Author
-
Cowan JF, Chandler AS, Kracen E, Park DR, Wallis CK, Liu E, Song C, Persing DH, and Fang FC
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cost-Benefit Analysis, DNA, Bacterial, Female, Hospitalization, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Mycobacterium tuberculosis isolation & purification, Prospective Studies, Reproducibility of Results, Sensitivity and Specificity, Sputum microbiology, Tuberculosis, Pulmonary transmission, Washington, Young Adult, Mycobacterium tuberculosis genetics, Nucleic Acid Amplification Techniques economics, Nucleic Acid Amplification Techniques methods, Tuberculosis, Pulmonary diagnosis, Tuberculosis, Pulmonary microbiology
- Abstract
Background: Microscopic examination of acid-fast-stained sputum smears is the current standard of care in the United States to determine airborne infection isolation (AII) of inpatients with presumptive pulmonary tuberculosis (PTB). However, nucleic acid amplification testing (NAAT) with the Xpert MTB/RIF assay (Xpert) may be more efficient and less costly., Methods: This prospective observational cohort study enrolled a consecutive sample of 318 AII-eligible inpatients from a public hospital in Seattle, Washington, from March 2012 to October 2013. Sputum samples were collected from each inpatient and analyzed using smear microscopy, culture, drug susceptibility testing, and NAAT. The performance, clinical utility (AII duration and survival), and cost-effectiveness from an institutional perspective were compared for 5 testing strategies., Results: Among the 318 admissions with presumptive PTB, 20 (6.3%) were culture-positive for Mycobacterium tuberculosis. The sensitivity of 1 Xpert, 2 Xperts, 2 smears, or 3 smears compared to culture was 0.85 (95% confidence interval [CI], .61–.96), 0.95 (95% CI, .73–1.0), 0.70 (95% CI, .46–.88), and 0.80 (95% CI, .56–.93), respectively. A cost-effectiveness analysis of the study results demonstrated that an Xpert test on 1 unconcentrated sputum sample (assuming equivalent results for unconcentrated and concentrated sputum samples) is the most cost-effective strategy (99.9% preferred at willingness-to-pay of US$50000) and on average would save 51.5 patient-hours in AII and up to $11466 relative to microscopy without a compromise in sensitivity., Conclusions: In hospitalized patients with presumptive PTB in a low-burden setting, NAAT can reduce AII and is comparably sensitive, more specific, and more cost-effective than smear microscopy.
- Published
- 2017
- Full Text
- View/download PDF
28. Correction: Analytical Performance Characteristics of the Cepheid GeneXpert Ebola Assay for the Detection of Ebola Virus.
- Author
-
Pinsky BA, Sahoo MK, Sandlund J, Kleman M, Kulkarni M, Grufman P, Nygren M, Kwiatkowski R, Baron EJ, Tenover F, Denison B, Higuchi R, Van Atta R, Beer NR, Carrillo AC, Naraghi-Arani P, Mire CE, Ranadheera C, Grolla A, Lagerqvist N, and Persing DH
- Published
- 2015
- Full Text
- View/download PDF
29. Analytical Performance Characteristics of the Cepheid GeneXpert Ebola Assay for the Detection of Ebola Virus.
- Author
-
Pinsky BA, Sahoo MK, Sandlund J, Kleman M, Kulkarni M, Grufman P, Nygren M, Kwiatkowski R, Baron EJ, Tenover F, Denison B, Higuchi R, Van Atta R, Beer NR, Carrillo AC, Naraghi-Arani P, Mire CE, Ranadheera C, Grolla A, Lagerqvist N, and Persing DH
- Subjects
- Animals, Chlorocebus aethiops, Ebolavirus physiology, Genes, Viral genetics, Hemorrhagic Fever, Ebola blood, Hemorrhagic Fever, Ebola virology, Host-Pathogen Interactions, Humans, RNA, Viral blood, RNA, Viral genetics, Reproducibility of Results, Sensitivity and Specificity, Time Factors, Vero Cells, Virus Inactivation, Ebolavirus genetics, Hemorrhagic Fever, Ebola diagnosis, Mass Screening methods, Nucleic Acid Amplification Techniques methods
- Abstract
Background: The recently developed Xpert® Ebola Assay is a novel nucleic acid amplification test for simplified detection of Ebola virus (EBOV) in whole blood and buccal swab samples. The assay targets sequences in two EBOV genes, lowering the risk for new variants to escape detection in the test. The objective of this report is to present analytical characteristics of the Xpert® Ebola Assay on whole blood samples., Methods and Findings: This study evaluated the assay's analytical sensitivity, analytical specificity, inclusivity and exclusivity performance in whole blood specimens. EBOV RNA, inactivated EBOV, and infectious EBOV were used as targets. The dynamic range of the assay, the inactivation of virus, and specimen stability were also evaluated. The lower limit of detection (LoD) for the assay using inactivated virus was estimated to be 73 copies/mL (95% CI: 51-97 copies/mL). The LoD for infectious virus was estimated to be 1 plaque-forming unit/mL, and for RNA to be 232 copies/mL (95% CI 163-302 copies/mL). The assay correctly identified five different Ebola viruses, Yambuku-Mayinga, Makona-C07, Yambuku-Ecran, Gabon-Ilembe, and Kikwit-956210, and correctly excluded all non-EBOV isolates tested. The conditions used by Xpert® Ebola for inactivation of infectious virus reduced EBOV titer by ≥6 logs., Conclusion: In summary, we found the Xpert® Ebola Assay to have high analytical sensitivity and specificity for the detection of EBOV in whole blood. It offers ease of use, fast turnaround time, and remote monitoring. The test has an efficient viral inactivation protocol, fulfills inclusivity and exclusivity criteria, and has specimen stability characteristics consistent with the need for decentralized testing. The simplicity of the assay should enable testing in a wide variety of laboratory settings, including remote laboratories that are not capable of performing highly complex nucleic acid amplification tests, and during outbreaks where time to detection is critical.
- Published
- 2015
- Full Text
- View/download PDF
30. mRNA biomarker detection in liquid-based cytology: a new approach in the prevention of cervical cancer.
- Author
-
Del Pino M, Svanholm-Barrie C, Torné A, Marimon L, Gaber J, Sagasta A, Persing DH, and Ordi J
- Subjects
- Antigens, Neoplasm analysis, Antigens, Neoplasm biosynthesis, Cell Cycle Proteins analysis, Cell Cycle Proteins biosynthesis, Cyclin-Dependent Kinase Inhibitor p16 analysis, Cyclin-Dependent Kinase Inhibitor p16 biosynthesis, Cytodiagnosis methods, DNA Topoisomerases, Type II analysis, DNA Topoisomerases, Type II biosynthesis, DNA, Viral analysis, DNA-Binding Proteins analysis, DNA-Binding Proteins biosynthesis, Female, Humans, Immunohistochemistry, Inhibitor of Apoptosis Proteins analysis, Inhibitor of Apoptosis Proteins biosynthesis, Intracellular Signaling Peptides and Proteins analysis, Intracellular Signaling Peptides and Proteins biosynthesis, Matrix Metalloproteinase 9 analysis, Matrix Metalloproteinase 9 biosynthesis, Nuclear Proteins analysis, Nuclear Proteins biosynthesis, Poly-ADP-Ribose Binding Proteins, Reverse Transcriptase Polymerase Chain Reaction, Sensitivity and Specificity, Survivin, Uterine Cervical Neoplasms prevention & control, Vaginal Smears, Uterine Cervical Dysplasia prevention & control, Biomarkers, Tumor genetics, Early Detection of Cancer methods, RNA, Messenger analysis, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Dysplasia diagnosis
- Abstract
Several high-risk human papillomavirus (HPV)-induced cell biomarkers have been proposed as possible candidates to identify patients harboring high-grade squamous intraepithelial lesions (HSILs) of the uterine cervix. We aimed to determine the feasibility of the detection of the mRNA of six biomarkers in cervical smear specimens obtained by liquid-based cytology and to evaluate whether this approach might be useful in the identification of patients with HSIL. One-hundred and twenty three women referred to colposcopy in the Hospital Clinic of Barcelona were included in the study. After a thorough study, including Pap test, high-risk HPV testing (Hybrid Capture 2 test), and colposcopy with directed biopsy and/or endocervical curettage, 48 patients were diagnosed with HSIL, whereas 75 were classified as negative (n=28), or harboring low-grade SIL (n=47). CDKN2A/p16, BIRC5, MMP9, TOP2A, MCM5, and MKI67 mRNA expression was analyzed by reverse transcription quantitative polymerase chain reaction in liquid-based cytology after the Pap test and Hybrid Capture 2 performance. The tissue expression of these biomarkers was analyzed by immunohistochemistry in the biopsy material. One-hundred and thirteen out of 123 (92%) liquid-based cytology yielded adequate material for mRNA analysis. TOP2A was the most sensitive (97%) biomarker for the detection of HSIL and CDKN2A/p16 the most specific (78%). The combination of TOP2A and CDKN2A/p16 showed a sensitivity of 96% (95% confidence interval (CI): 88-99) and a specificity of 71% (95% CI: 55-82). In the immunohistochemistry analysis, all biomarkers showed a high sensitivity but low specificity for HSIL, except CDKN2A/p16 which had a sensitivity of 100% and a specificity of 63%. The combination of TOP2A and CDKN2A/p16 showed a sensitivity of 100% (95% CI: 91-100) and a specificity of 43% (95% CI: 32-55). The detection of mRNA of cell biomarkers in liquid-based cytology material is feasible. The combination TOP2A and CDKN2A/p16 has a good balance between sensitivity and specificity for the detection of women with HSIL.
- Published
- 2015
- Full Text
- View/download PDF
31. Latent tuberculosis: interferon and beyond?
- Author
-
Persing DH
- Subjects
- Female, Humans, Male, Antigens, Bacterial pharmacology, Blood Cells drug effects, Chemokine CXCL9 genetics, Latent Tuberculosis diagnosis, Tuberculosis, Pulmonary diagnosis, Tumor Necrosis Factor-alpha genetics
- Published
- 2015
- Full Text
- View/download PDF
32. Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States, 2011 to 2013.
- Author
-
Tickler IA, Goering RV, Whitmore JD, Lynn AN, Persing DH, and Tenover FC
- Subjects
- Clindamycin pharmacology, Clostridioides difficile isolation & purification, Clostridium Infections drug therapy, Clostridium Infections microbiology, Feces microbiology, Fluoroquinolones pharmacology, Humans, Microbial Sensitivity Tests, Moxifloxacin, United States, Vancomycin pharmacology, Vancomycin Resistance, Anti-Bacterial Agents pharmacology, Clostridioides difficile classification, Clostridioides difficile drug effects, Drug Resistance, Multiple, Bacterial genetics, Ribotyping
- Abstract
We determined the PCR ribotypes and antimicrobial susceptibility patterns of 508 toxigenic Clostridium difficile isolates collected between 2011 and 2013 from 32 U.S. hospitals. Of the 29 PCR ribotypes identified, the 027 strain type was the most common (28.1%), although the rates varied by geographic region. Ribotype 014/020 isolates appear to be emerging. Clindamycin and moxifloxacin resistances (36.8% and 35.8%, respectively) were the most frequent resistance phenotypes observed. Reduced susceptibility to vancomycin was observed in 39.1% of 027 isolates., (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)
- Published
- 2014
- Full Text
- View/download PDF
33. Detection of colonization by carbapenemase-producing Gram-negative Bacilli in patients by use of the Xpert MDRO assay.
- Author
-
Tenover FC, Canton R, Kop J, Chan R, Ryan J, Weir F, Ruiz-Garbajosa P, LaBombardi V, and Persing DH
- Subjects
- Bacterial Proteins metabolism, Bacteriological Techniques methods, Carrier State microbiology, Feces microbiology, Gram-Negative Bacteria genetics, Gram-Negative Bacterial Infections microbiology, Humans, Perineum microbiology, Rectum microbiology, Sensitivity and Specificity, beta-Lactamases metabolism, Bacterial Proteins genetics, Carrier State diagnosis, Gram-Negative Bacteria enzymology, Gram-Negative Bacteria isolation & purification, Gram-Negative Bacterial Infections diagnosis, Molecular Diagnostic Techniques methods, Polymerase Chain Reaction methods, beta-Lactamases genetics
- Abstract
Detecting colonization of patients with carbapenemase-producing bacteria can be difficult. This study compared the sensitivity and specificity of a PCR-based method (Xpert MDRO) for detecting blaKPC, blaNDM, and blaVIM carbapenem resistance genes using GeneXpert cartridges to the results of culture with and without a broth enrichment step on 328 rectal, perirectal, and stool samples. The culture method included direct inoculation of a MacConkey agar plate on which a 10-μg meropenem disk was placed and plating on MacConkey agar after overnight enrichment of the sample in MacConkey broth containing 1 μg/ml of meropenem. Forty-three (13.1%) samples were positive by PCR for blaKPC and 11 (3.4%) were positive for blaVIM; none were positive for blaNDM. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the PCR assay for blaKPC were 100%, 99.0%, 93.0%, and 100%, respectively, compared to broth enrichment culture and sequencing of target genes. The sensitivity, specificity, PPV, and NPV of the assay for blaVIM were 100%, 99.4%, 81.8%, and 100%, respectively. Since none of the clinical samples contained organisms with blaNDM, 66 contrived stool samples were prepared at various dilutions using three Klebsiella pneumoniae isolates containing blaNDM. The PCR assay showed 100% positivity at dilutions from 300 to 1,800 CFU/ml and 93.3% at 150 CFU/ml. The Xpert MDRO PCR assay required 2 min of hands-on time and 47 min to complete. Rapid identification of patients colonized with carbapenemase-producing organisms using multiplex PCR may help hospitals to improve infection control activities.
- Published
- 2013
- Full Text
- View/download PDF
34. Genome-wide sequencing of cellular microRNAs identifies a combinatorial expression signature diagnostic of sepsis.
- Author
-
Ma Y, Vilanova D, Atalar K, Delfour O, Edgeworth J, Ostermann M, Hernandez-Fuentes M, Razafimahatratra S, Michot B, Persing DH, Ziegler I, Törös B, Mölling P, Olcén P, Beale R, and Lord GM
- Subjects
- Adult, Biomarkers blood, Cohort Studies, Female, Genome-Wide Association Study, High-Throughput Nucleotide Sequencing, Humans, Intensive Care Units, Linear Models, Male, MicroRNAs genetics, Middle Aged, Monocytes pathology, Prognosis, Real-Time Polymerase Chain Reaction, Sepsis genetics, Sepsis pathology, MicroRNAs blood, Monocytes metabolism, Sepsis blood, Sepsis diagnosis, Transcriptome
- Abstract
Rationale: Sepsis is a common cause of death in the intensive care unit with mortality up to 70% when accompanied by multiple organ dysfunction. Rapid diagnosis and the institution of appropriate antibiotic therapy and pressor support are therefore critical for survival. MicroRNAs are small non-coding RNAs that play an important role in the regulation of numerous cellular processes, including inflammation and immunity., Objectives: We hypothesized changes in expression of microRNAs during sepsis may be of diagnostic value in the intensive care unit (ICU)., Methods: Massively parallel sequencing of microRNAs was utilised for screening microRNA candidates. Putative microRNAs were validated using quantitative real-time PCR (qRT-PCR). This study includes data from both a training cohort (UK) and an independent validation cohort (Sweden). A linear discriminant statistical model was employed to construct a diagnostic microRNA signature., Results: A panel of known and novel microRNAs were detectable in the blood of patients with sepsis. After qRT-PCR validation, microRNA miR-150 and miR-4772-5p-iso were able to discriminate between patients who have systemic inflammatory response syndrome and patients with sepsis. This finding was also validated in independent cohort with an average diagnostic accuracy of 86%. Fractionating the cellular components of blood reveals miR-4772-5p-iso is expressed differentially in monocytes. Functional experiments using primary human monocytes demonstrate that it expressed in response to TLR ligation., Conclusions: Taken together, these data provide a novel microRNA signature of sepsis that should allow rapid point-of-care diagnostic assessment of patients on ICU and also provide greater insight into the pathobiology of this severe disease.
- Published
- 2013
- Full Text
- View/download PDF
35. Alternative processing of the U2 small nuclear RNA produces a 19-22nt fragment with relevance for the detection of non-small cell lung cancer in human serum.
- Author
-
Mazières J, Catherinne C, Delfour O, Gouin S, Rouquette I, Delisle MB, Prévot G, Escamilla R, Didier A, Persing DH, Bates M, and Michot B
- Subjects
- Carcinoma, Non-Small-Cell Lung complications, DNA Primers genetics, France, High-Throughput Nucleotide Sequencing, Humans, Microarray Analysis methods, Pulmonary Disease, Chronic Obstructive complications, Real-Time Polymerase Chain Reaction, Sensitivity and Specificity, Carcinoma, Non-Small-Cell Lung blood, Carcinoma, Non-Small-Cell Lung diagnosis, MicroRNAs blood, MicroRNAs genetics, Pulmonary Disease, Chronic Obstructive blood, RNA, Small Nuclear blood, RNA, Small Nuclear genetics
- Abstract
RNU2 exists in two functional forms (RNU2-1 and RNU2-2) distinguishable by the presence of a unique 4-bases motif. Detailed investigation of datasets obtained from deep sequencing of five human lung primary tumors revealed that both forms express at a high rate a 19-22nt fragment (miR-U2-1 and -2) from its 3' region and contains the 4-bases motif. Deep sequencing of independent pools of serum samples from healthy donors and lung cancer patients revealed that miR-U2-1 and -2 are pervasively processed in lung tissue by means of endonucleolytic cleavages and stably exported to the blood. Then, microarrays hybridization experiments of matched normal/tumor samples revealed a significant over-expression of miR-U2-1 in 14 of 18 lung primary tumors. Subsequently, qRT-PCR of miR-U2-1 using serum from 62 lung cancer patients and 96 various controls demonstrated that its expression levels identify lung cancer patients with 79% sensitivity and 80% specificity. miR-U2-1 expression correlated with the presence or absence of lung cancer in patients with chronic obstructive pulmonary disease (COPD), other diseases of the lung - not cancer, and in healthy controls. These data suggest that RNU2-1 is a new bi-functional ncRNA that produces a 19-22nt fragment which may be useful in detecting lung cancer non-invasively in high risk patients.
- Published
- 2013
- Full Text
- View/download PDF
36. Antimicrobial-resistant strains of Clostridium difficile from North America.
- Author
-
Tenover FC, Tickler IA, and Persing DH
- Subjects
- Aza Compounds pharmacology, Clindamycin pharmacology, Fluoroquinolones, Microbial Sensitivity Tests, Moxifloxacin, North America, Quinolines pharmacology, Ribotyping, Rifampin pharmacology, Anti-Bacterial Agents pharmacology, Clostridioides difficile drug effects, Clostridioides difficile genetics, Drug Resistance, Multiple, Bacterial genetics
- Abstract
A total of 316 toxigenic Clostridium difficile clinical isolates of known PCR ribotypes from patients in North America were screened for resistance to clindamycin, metronidazole, moxifloxacin, and rifampin. Clindamycin resistance was observed among 16 different ribotypes, with ribotypes 017, 053, and 078 showing the highest proportions of resistance. All isolates were susceptible to metronidazole. Moxifloxacin resistance was present in >90% of PCR-ribotype 027 and 053 isolates but was less common among other ribotypes. Only 7.9% of the C. difficile isolates were resistant to rifampin. Multidrug resistance (clindamycin, moxifloxacin, and rifampin) was present in 27.5% of PCR-ribotype 027 strains but was rare in other ribotypes. These results suggest that antimicrobial resistance in North American isolates of C. difficile varies by strain type and parallels rates of resistance reported from Europe and the Far East.
- Published
- 2012
- Full Text
- View/download PDF
37. Characterization of nasal and blood culture isolates of methicillin-resistant Staphylococcus aureus from patients in United States Hospitals.
- Author
-
Tenover FC, Tickler IA, Goering RV, Kreiswirth BN, Mediavilla JR, and Persing DH
- Subjects
- Bacteremia drug therapy, Bacteremia epidemiology, Bacterial Proteins genetics, Bacterial Typing Techniques, Clindamycin administration & dosage, Cross Infection drug therapy, Cross Infection epidemiology, Drug Resistance, Bacterial, Electrophoresis, Gel, Pulsed-Field, Humans, Methicillin-Resistant Staphylococcus aureus genetics, Methicillin-Resistant Staphylococcus aureus isolation & purification, Microbial Sensitivity Tests, Mupirocin administration & dosage, Nasal Cavity microbiology, Prevalence, Retrospective Studies, Staphylococcal Infections drug therapy, Staphylococcal Infections epidemiology, Tobramycin administration & dosage, United States epidemiology, Anti-Bacterial Agents administration & dosage, Bacteremia microbiology, Cross Infection microbiology, Methicillin-Resistant Staphylococcus aureus drug effects, Staphylococcal Infections microbiology
- Abstract
A total of 299 nares and 194 blood isolates of methicillin-resistant Staphylococcus aureus (MRSA), each recovered from a unique patient, were collected from 23 U.S. hospitals from May 2009 to March 2010. All isolates underwent spa and staphylococcal cassette chromosome mec element (SCCmec) typing and antimicrobial susceptibility testing; a subset of 84 isolates was typed by pulsed-field gel electrophoresis (PFGE) using SmaI. Seventy-six spa types were observed among the isolates. Overall, for nasal isolates, spa type t002-SCCmec type II (USA100) was the most common strain type (37% of isolates), while among blood isolates, spa type t008-SCCmec type IV (USA300) was the most common (39%). However, the proportion of all USA100 and USA300 isolates varied by United States census region. Nasal isolates were more resistant to tobramycin and clindamycin than blood isolates (55.9% and 48.8% of isolates versus 36.6% and 39.7%, respectively; for both, P < 0.05). The USA300 isolates were largely resistant to fluoroquinolones. High-level mupirocin resistance was low among all spa types (<5%). SCCmec types III and VIII, which are rare in the United States, were observed along with several unusual PFGE types, including CMRSA9, EMRSA15, and the PFGE profile associated with sequence type 239 (ST239) isolates. Typing data from this convenience sample suggest that in U.S. hospitalized patients, USA100 isolates of multiple spa types, while still common in the nares, have been replaced by USA300 isolates as the predominant MRSA strain type in positive blood cultures.
- Published
- 2012
- Full Text
- View/download PDF
38. Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty?
- Author
-
Tenover FC, Baron EJ, Peterson LR, and Persing DH
- Subjects
- Bacterial Proteins analysis, Clostridioides difficile genetics, Glutamate Dehydrogenase analysis, Humans, Polymerase Chain Reaction methods, Clostridioides difficile isolation & purification, Clostridium Infections diagnosis, Enterocolitis, Pseudomembranous diagnosis, Molecular Diagnostic Techniques methods, Nucleic Acid Amplification Techniques
- Abstract
The laboratory diagnosis of Clostridium difficile infection (CDI) continues to be challenging. Recent guidelines from professional societies in the United States note that enzyme immunoassays for toxins A and B do not have adequate sensitivity to be used alone for detecting CDI, yet the optimal method for diagnosing this infection remains unclear. Nucleic acid amplification tests (NAATs) that target chromosomal toxin genes (usually the toxin B gene, tcdB) show high sensitivity and specificity, provide rapid results, and are amenable to both batch and on-demand testing, but these tests were not universally recommended for routine use in the recent guidelines. Rather, two-step algorithms that use glutamate dehydrogenase (GDH) assays to screen for C. difficile in stool specimens, followed by either direct cytotoxin testing or culture to identify toxin-producing C. difficile isolates, were recommended in one guideline and either GDH algorithms or NAATs were recommended in another guideline. Unfortunately, neither culture nor direct cytotoxin testing is widely available. In addition, this two-step approach requires 48 to 92 hours to complete, which may delay the initiation of therapy and critical infection control measures. Recent studies also show the sensitivity of several GDH assays to be <90%. This review considers the role of NAATs for diagnosing CDI and explores their potential advantages over two-step algorithms, including shorter time to results, while providing comparable, if not superior, accuracy., (Copyright © 2011 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
39. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay.
- Author
-
Blakemore R, Nabeta P, Davidow AL, Vadwai V, Tahirli R, Munsamy V, Nicol M, Jones M, Persing DH, Hillemann D, Ruesch-Gerdes S, Leisegang F, Zamudio C, Rodrigues C, Boehme CC, Perkins MD, and Alland D
- Subjects
- Algorithms, Bacterial Proteins analysis, Bacterial Proteins genetics, DNA, Bacterial genetics, Humans, Multicenter Studies as Topic, Mycobacterium tuberculosis genetics, Predictive Value of Tests, Randomized Controlled Trials as Topic, Real-Time Polymerase Chain Reaction, Research Design, Sensitivity and Specificity, Tuberculosis microbiology, Microscopy, Mycobacterium tuberculosis isolation & purification, Nucleic Acid Amplification Techniques, Sputum microbiology, Tuberculosis diagnosis
- Abstract
Rationale: The Xpert MTB/RIF is an automated molecular test for Mycobacterium tuberculosis that estimates bacterial burden by measuring the threshold-cycle (Ct) of its M. tuberculosis-specific real-time polymerase chain reaction. Bacterial burden is an important biomarker for disease severity, infection control risk, and response to therapy., Objectives: Evaluate bacterial load quantitation by Xpert MTB/RIF compared with conventional quantitative methods., Methods: Xpert MTB/RIF results were compared with smear-microscopy, semiquantiative solid culture, and time-to-detection in liquid culture for 741 patients and 2,008 samples tested in a multisite clinical trial. An internal control real-time polymerase chain reaction was evaluated for its ability to identify inaccurate quantitative Xpert MTB/RIF results., Measurements and Main Results: Assays with an internal control Ct greater than 34 were likely to be inaccurately quantitated; this represented 15% of M. tuberculosis-positive tests. Excluding these, decreasing M. tuberculosis Ct was associated with increasing smear microscopy grade for smears of concentrated sputum pellets (r(s) = -0.77) and directly from sputum (r(s) =-0.71). A Ct cutoff of approximately 27.7 best predicted smear-positive status. The association between M. tuberculosis Ct and time-to-detection in liquid culture (r(s) = 0.68) and semiquantitative colony counts (r(s) = -0.56) was weaker than smear. Tests of paired same-patient sputum showed that high viscosity sputum samples contained ×32 more M. tuberculosis than nonviscous samples. Comparisons between the grade of the acid-fast bacilli smear and Xpert MTB/RIF quantitative data across study sites enabled us to identify a site outlier in microscopy., Conclusions: Xpert MTB/RIF quantitation offers a new, standardized approach to measuring bacterial burden in the sputum of patients with tuberculosis.
- Published
- 2011
- Full Text
- View/download PDF
40. Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals.
- Author
-
Tenover FC, Tickler I, Armstrong ES, Kubo A, Lopez S, Persing DH, and Miller GH
- Subjects
- Aminoglycosides genetics, Aminoglycosides pharmacology, Anti-Bacterial Agents therapeutic use, Blood microbiology, Drug Resistance, Bacterial genetics, Hospitals, Humans, Methicillin-Resistant Staphylococcus aureus isolation & purification, Microbial Sensitivity Tests, Nose microbiology, Sisomicin pharmacology, Sisomicin therapeutic use, Staphylococcal Infections microbiology, Tobramycin pharmacology, United States, Anti-Bacterial Agents pharmacology, Methicillin Resistance genetics, Methicillin-Resistant Staphylococcus aureus drug effects, Sisomicin analogs & derivatives, Staphylococcal Infections drug therapy
- Abstract
The activity of ACHN-490 was evaluated against 493 meticillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2009-2010 from 23 US hospitals. The MIC(50) and MIC(90) values (minimal inhibitory concentrations for 50% and 90% of the organisms, respectively) for ACHN-490 were 1 and 2 μg/mL compared with 8 and 32 μg/mL for amikacin, 0.5 and 1 μg/mL for gentamicin and 2 and >16 μg/mL for tobramycin. The gene encoding the aminoglycoside-modifying enzyme APH(2″)-Ia/AAC(6')-Ie was present in 12% of the subset of 84 isolates examined by polymerase chain reaction (PCR), whilst the gene encoding ANT(4')-Ia was present in 89% of isolates. ACHN-490 activity was not affected by either enzyme., (Copyright © 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
41. Comparison of strain typing results for Clostridium difficile isolates from North America.
- Author
-
Tenover FC, Akerlund T, Gerding DN, Goering RV, Boström T, Jonsson AM, Wong E, Wortman AT, and Persing DH
- Subjects
- Canada, Clostridioides difficile isolation & purification, Cluster Analysis, Electrophoresis, Gel, Pulsed-Field, Genotype, Humans, Molecular Epidemiology methods, Polymorphism, Restriction Fragment Length, Prohibitins, Ribotyping, United States, Bacterial Typing Techniques methods, Clostridioides difficile classification, Clostridioides difficile genetics, Clostridium Infections microbiology, Molecular Typing methods
- Abstract
Accurate strain typing is critical for understanding the changing epidemiology of Clostridium difficile infections. We typed 350 isolates of toxigenic C. difficile from 2008 to 2009 from seven laboratories in the United States and Canada. Typing was performed by PCR-ribotyping, pulsed-field gel electrophoresis (PFGE), and restriction endonuclease analysis (REA) of whole-cell DNA. The Cepheid Xpert C. difficile test for presumptive identification of 027/NAP1/BI isolates was also tested directly on original stool samples. Of 350 isolates, 244 (70%) were known PCR ribotypes, 224 (68%) were 1 of 8 common REA groups, and 187 (54%) were known PFGE types. Eighty-four isolates typed as 027, NAP1, and BI, and 83 of these were identified as presumptive 027/NAP1/BI by Xpert C. difficile. Eight additional isolates were called presumptive 027/NAP1/BI by Xpert C. difficile, of which three were ribotype 027. Five PCR ribotypes contained multiple REA groups, and three North American pulsed-field (NAP) profiles contained both multiple REA groups and PCR ribotypes. There was modest concordance of results among the three methods for C. difficile strains, including the J strain (ribotype 001 and PFGE NAP2), the toxin A-negative 017 strain (PFGE NAP9 and REA type CF), the 078 animal strain (PFGE NAP7 and REA type BK), and type 106 (PFGE NAP11 and REA type DH). PCR-ribotyping, REA, and PFGE provide different but overlapping patterns of strain clustering. Unlike the other methods, the Xpert C. difficile 027/NAP1/BI assay gave results directly from stool specimens, required only 45 min to complete, but was limited to detection of a single strain type.
- Published
- 2011
- Full Text
- View/download PDF
42. Evaluation of a rapid and completely automated real-time reverse transcriptase PCR assay for diagnosis of enteroviral meningitis.
- Author
-
Nolte FS, Rogers BB, Tang YW, Oberste MS, Robinson CC, Kehl KS, Rand KA, Rotbart HA, Romero JR, Nyquist AC, and Persing DH
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cerebrospinal Fluid virology, Child, Child, Preschool, Enterovirus isolation & purification, Enterovirus Infections virology, Female, Humans, Infant, Infant, Newborn, Male, Meningitis, Viral virology, Middle Aged, Prevalence, RNA, Viral cerebrospinal fluid, Sensitivity and Specificity, Time Factors, United States, Young Adult, Enterovirus classification, Enterovirus genetics, Enterovirus Infections diagnosis, Meningitis, Viral diagnosis, Reverse Transcriptase Polymerase Chain Reaction methods, Virology methods
- Abstract
Nucleic acid amplification tests (NAATs) for enterovirus RNA in cerebrospinal fluid (CSF) have emerged as the new gold standard for diagnosis of enteroviral meningitis, and their use can improve the management and decrease the costs for caring for children with enteroviral meningitis. The Xpert EV assay (Cepheid, Sunnyvale, CA) is a rapid, fully automated real-time PCR test for the detection of enterovirus RNA that was approved by the U.S. Food and Drug Administration for in vitro diagnostic use in March 2007. In this multicenter trial we established the clinical performance characteristics of the Xpert EV assay in patients presenting with meningitis symptoms relative to clinical truth. Clinical truth for enteroviral meningitis was defined as clinical evidence of meningitis, the absence of another detectable pathogen in CSF, and detection of enterovirus in CSF either by two reference NAATs or by viral culture. A total of 199 prospectively and 235 retrospectively collected specimens were eligible for inclusion in this study. The overall prevalence of enteroviral meningitis was 26.04%. The Xpert EV assay had a sensitivity of 94.69% (90% confidence interval [CI] = 89.79 to 97.66%), specificity of 100% (90% CI = 99.07 to 100%), positive predictive value of 100%, negative predictive value of 98.17, and an accuracy of 98.62% relative to clinical truth. The Xpert EV assay demonstrated a high degree of accuracy for diagnosis of enteroviral meningitis. The simplicity and on-demand capability of the Xpert EV assay should prove to be a valuable adjunct to the evaluation of suspected meningitis cases.
- Published
- 2011
- Full Text
- View/download PDF
43. Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches.
- Author
-
Tenover FC, Novak-Weekley S, Woods CW, Peterson LR, Davis T, Schreckenberger P, Fang FC, Dascal A, Gerding DN, Nomura JH, Goering RV, Akerlund T, Weissfeld AS, Baron EJ, Wong E, Marlowe EM, Whitmore J, and Persing DH
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Bacterial Typing Techniques methods, Child, Child, Preschool, Feces microbiology, Female, Humans, Immunoenzyme Techniques methods, Male, Middle Aged, Ribotyping methods, Sensitivity and Specificity, Toxicity Tests methods, Young Adult, Bacteriological Techniques methods, Clostridioides difficile isolation & purification, Clostridium Infections diagnosis, Molecular Diagnostic Techniques methods
- Abstract
A multicenter clinical trial assessed the performance of the Cepheid Xpert C. difficile assay on stool specimens collected from patients suspected of having Clostridium difficile infection (CDI). A total of 2,296 unformed stool specimens, collected from seven study sites, were tested by Xpert C. difficile enrichment culture followed by cell culture cytotoxicity testing of the isolates (i.e., toxigenic culture with enrichment) and the study sites' standard C. difficile test methods. The methods included enzyme immunoassay (EIA), direct cytotoxin testing, and two- and three-step algorithms using glutamate dehydrogenase (GDH) screening followed by either EIA or EIA and an in-house PCR assay. All C. difficile strains were typed by PCR-ribotyping. Compared to results for toxigenic culture with enrichment, the sensitivity, specificity, and positive and negative predictive values of the Xpert assay were 93.5, 94.0, 73.0, and 98.8%, respectively. The overall sensitivity of the EIAs compared to that of enrichment culture was 60.0%, and the sensitivity of combined GDH algorithms was 72.9%; both were significantly lower than that of Xpert C. difficile (P < 0.001 and P = 0.03, respectively). The sensitivity of the EIA was significantly lower than that of the Xpert C. difficile assay for detection of ribotypes 002, 027, and 106 (P < 0.0001, P < 0.0001, and P = 0.004, respectively, Fisher's exact test), and the sensitivity of GDH algorithms for ribotypes other than 027 was lower than that for Xpert C. difficile (P < 0.001). The Xpert C. difficile assay is a simple, rapid, and accurate method for detection of toxigenic C. difficile in unformed stool specimens and is minimally affected by strain type compared to EIA and GDH-based methods.
- Published
- 2010
- Full Text
- View/download PDF
44. Rapid molecular detection of tuberculosis and rifampin resistance.
- Author
-
Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, and Perkins MD
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Bacterial Proteins genetics, DNA-Directed RNA Polymerases, Female, Humans, Male, Microbial Sensitivity Tests methods, Middle Aged, Mycobacterium tuberculosis genetics, Polymerase Chain Reaction instrumentation, Prospective Studies, Reference Standards, Sensitivity and Specificity, Sputum microbiology, Tuberculosis diagnosis, Tuberculosis, Multidrug-Resistant microbiology, Young Adult, Antitubercular Agents pharmacology, Drug Resistance, Bacterial, Mycobacterium tuberculosis drug effects, Polymerase Chain Reaction methods, Rifampin pharmacology, Tuberculosis microbiology, Tuberculosis, Multidrug-Resistant diagnosis
- Abstract
Background: Global control of tuberculosis is hampered by slow, insensitive diagnostic methods, particularly for the detection of drug-resistant forms and in patients with human immunodeficiency virus infection. Early detection is essential to reduce the death rate and interrupt transmission, but the complexity and infrastructure needs of sensitive methods limit their accessibility and effect., Methods: We assessed the performance of Xpert MTB/RIF, an automated molecular test for Mycobacterium tuberculosis (MTB) and resistance to rifampin (RIF), with fully integrated sample processing in 1730 patients with suspected drug-sensitive or multidrug-resistant pulmonary tuberculosis. Eligible patients in Peru, Azerbaijan, South Africa, and India provided three sputum specimens each. Two specimens were processed with N-acetyl-L-cysteine and sodium hydroxide before microscopy, solid and liquid culture, and the MTB/RIF test, and one specimen was used for direct testing with microscopy and the MTB/RIF test., Results: Among culture-positive patients, a single, direct MTB/RIF test identified 551 of 561 patients with smear-positive tuberculosis (98.2%) and 124 of 171 with smear-negative tuberculosis (72.5%). The test was specific in 604 of 609 patients without tuberculosis (99.2%). Among patients with smear-negative, culture-positive tuberculosis, the addition of a second MTB/RIF test increased sensitivity by 12.6 percentage points and a third by 5.1 percentage points, to a total of 90.2%. As compared with phenotypic drug-susceptibility testing, MTB/RIF testing correctly identified 200 of 205 patients (97.6%) with rifampin-resistant bacteria and 504 of 514 (98.1%) with rifampin-sensitive bacteria. Sequencing resolved all but two cases in favor of the MTB/RIF assay., Conclusions: The MTB/RIF test provided sensitive detection of tuberculosis and rifampin resistance directly from untreated sputum in less than 2 hours with minimal hands-on time. (Funded by the Foundation for Innovative New Diagnostics.)
- Published
- 2010
- Full Text
- View/download PDF
45. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology.
- Author
-
Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR, Rodgers R, Banada P, Safi H, Blakemore R, Lan NT, Jones-López EC, Levi M, Burday M, Ayakaka I, Mugerwa RD, McMillan B, Winn-Deen E, Christel L, Dailey P, Perkins MD, Persing DH, and Alland D
- Subjects
- Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Mycobacterium tuberculosis isolation & purification, Polymerase Chain Reaction methods, Sensitivity and Specificity, Sputum microbiology, Tuberculosis microbiology, Uganda, Vietnam, Young Adult, Antitubercular Agents pharmacology, Bacteriological Techniques methods, Drug Resistance, Bacterial, Mycobacterium tuberculosis drug effects, Point-of-Care Systems, Rifampin pharmacology, Tuberculosis diagnosis
- Abstract
Current nucleic acid amplification methods to detect Mycobacterium tuberculosis are complex, labor-intensive, and technically challenging. We developed and performed the first analysis of the Cepheid Gene Xpert System's MTB/RIF assay, an integrated hands-free sputum-processing and real-time PCR system with rapid on-demand, near-patient technology, to simultaneously detect M. tuberculosis and rifampin resistance. Analytic tests of M. tuberculosis DNA demonstrated a limit of detection (LOD) of 4.5 genomes per reaction. Studies using sputum spiked with known numbers of M. tuberculosis CFU predicted a clinical LOD of 131 CFU/ml. Killing studies showed that the assay's buffer decreased M. tuberculosis viability by at least 8 logs, substantially reducing biohazards. Tests of 23 different commonly occurring rifampin resistance mutations demonstrated that all 23 (100%) would be identified as rifampin resistant. An analysis of 20 nontuberculosis mycobacteria species confirmed high assay specificity. A small clinical validation study of 107 clinical sputum samples from suspected tuberculosis cases in Vietnam detected 29/29 (100%) smear-positive culture-positive cases and 33/39 (84.6%) or 38/53 (71.7%) smear-negative culture-positive cases, as determined by growth on solid medium or on both solid and liquid media, respectively. M. tuberculosis was not detected in 25/25 (100%) of the culture-negative samples. A study of 64 smear-positive culture-positive sputa from retreatment tuberculosis cases in Uganda detected 63/64 (98.4%) culture-positive cases and 9/9 (100%) cases of rifampin resistance. Rifampin resistance was excluded in 54/55 (98.2%) susceptible cases. Specificity rose to 100% after correcting for a conventional susceptibility test error. In conclusion, this highly sensitive and simple-to-use system can detect M. tuberculosis directly from sputum in less than 2 h.
- Published
- 2010
- Full Text
- View/download PDF
46. Prevalence and management of invalid GeneXpert enterovirus results obtained with cerebrospinal fluid samples: a 2-year study.
- Author
-
Sefers SE, Raymer AK, Kilby JT, Persing DH, and Tang YW
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Freezing, Humans, Infant, Infant, Newborn, Male, Middle Aged, Sensitivity and Specificity, Young Adult, Cerebrospinal Fluid virology, Diagnostic Errors prevention & control, Diagnostic Errors statistics & numerical data, Enterovirus Infections diagnosis, Molecular Diagnostic Techniques methods, Reagent Kits, Diagnostic
- Abstract
A total of 525 cerebrospinal fluid (CSF) samples submitted during the 2007 and 2008 enteroviral seasons were included in a study to determine the prevalence of and potential risk factors for invalid Cepheid GeneXpert enterovirus assay (GXEA) results, as well as possible solutions for the problem. The invalid GXEA results were reported for 43 (8.2%) specimens and correlated with increased visibility of red blood cells (P < 0.0001) but not with CSF xanthochromia and clotting. Invalid GXEA result rates were markedly diminished by 82.1% and 96.0% and test sensitivities were minimally decreased by 1.7% and 3.6% when these specimens were tested at a 1:5 dilution and after a freeze-thaw cycle, respectively.
- Published
- 2009
- Full Text
- View/download PDF
47. Democratizing molecular diagnostics: the GeneXpert(®) enterovirus assay.
- Author
-
Patel SR, Weir F, Dailey P, and Persing DH
- Abstract
Background: Few clinical scenarios are as diagnostically demanding as the workup of acute meningitis in the emergency room setting. In humans, most cases of meningitis are due to enteroviral infection, which usually resolves with supportive care and does not generally require hospitalization. The difficulty in evaluating meningitis is often related to its nonspecific presentation; rapid identification of the underlying etiologic agent is critical to selection of the most appropriate course of therapy., Objective: To develop a rapid, automated polymerase chain reaction-based test for enteroviral meningitis that can be run on demand, and to make the test easy enough to operate that most hospital laboratories can offer it on an immediate basis in order to provide maximum medical impact., Methods: A sensitive and specific test on the GeneXpert was developed for detection of enteroviral RNA in cerebrospinal fluid. The automated test was carried out in a disposable GeneXpert cartridge, which conducts the steps of nucleic acid purification, amplification and detection of enteroviral genomic RNA in ∼ 2 h. Preclinical and clinical studies showed sensitivities of 97.1 and 98%, respectively, and specificities of 100 and 97.1%, respectively. In February 2006, the test received FDA clearance as an aid in the diagnosis of viral meningitis., Conclusions: Rapid and accurate molecular diagnostic testing for enterovirus infection provides clinicians with information they need to make the best patient decisions in managing patients with meningitis. The GeneXpert enterovirus assay features on-demand availability and a level of simplicity that allows nearly any hospital laboratory to offer a sophisticated test that was once the exclusive domain of reference laboratories.
- Published
- 2009
- Full Text
- View/download PDF
48. GeneXpert enterovirus assay: one-year experience in a routine laboratory setting and evaluation on three proficiency panels.
- Author
-
Seme K, Mocilnik T, Komlos KF, Doplihar A, Persing DH, and Poljak M
- Subjects
- Enterovirus genetics, Enterovirus Infections diagnosis, Enterovirus Infections virology, Humans, Sensitivity and Specificity, Enterovirus isolation & purification, Meningitis, Viral diagnosis, Meningitis, Viral virology, RNA, Viral cerebrospinal fluid, Reagent Kits, Diagnostic, Reverse Transcriptase Polymerase Chain Reaction methods
- Abstract
A prospective unblinded comparative evaluation of three assays for the detection of enteroviral RNA performed on 83 positive and 79 negative cerebrospinal fluid samples showed initial and resolved sensitivities of 90.4% and 98.8%, respectively, for the Cepheid GeneXpert enterovirus assay; 94.0% and 97.6%, respectively, for the Argene enterovirus consensus kit; and 100% and 100%, respectively, for an in-house real-time PCR. The initial and resolved specificities were 100% for all three assays.
- Published
- 2008
- Full Text
- View/download PDF
49. Babesia microti and Borrelia burgdorferi coinfection associated with increased severity of arthritis.
- Author
-
Moro MH, Zegarra-Moro OL, and Persing DH
- Subjects
- Animals, Arthritis physiopathology, Disease Models, Animal, Mice, Mice, Inbred C3H, Arthritis microbiology, Babesia microti, Babesiosis complications, Borrelia burgdorferi, Lyme Disease complications
- Published
- 2006
- Full Text
- View/download PDF
50. Decreased levels of interleukin-12p40 in the serum of patients with Whipple's disease.
- Author
-
Kalt A, Schneider T, Ring S, Hoffmann J, Zeitz M, Stallmach A, Persing DH, and Marth T
- Subjects
- Biomarkers blood, Disease Progression, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoglobulin G blood, Interleukin-12 blood, Male, Middle Aged, Severity of Illness Index, Tumor Necrosis Factor-alpha blood, Interleukin-12 Subunit p40 blood, Whipple Disease blood
- Abstract
Background: An impaired production of interleukin (IL)-12 and T cell interferon-gamma (IFN-gamma) of in vitro stimulated monocytes has been discussed as a pathogenic factor in Whipple's disease (WD). It is unclear whether this defect of cellular immunity is translated to the humoral immune system and to serum correlates., Methods: We analyzed the serum of 40 patients with Whipple's disease in various degrees of disease activity by sandwich enzyme-linked immunosorbent assay for differences in cytokine and cell adhesion molecule concentrations compared with age- and sex-matched controls., Results: We observed a highly significant reduction of IL-12p40 levels (patients, 0.18+/-0.05 ng/ml (mean+/-SEM); controls, 3.19+/-0.39 ng/ml; p<0.01) in all stages of disease activity, whereas the concentration of IL-12p70 was comparable with controls. Furthermore, we observed a slight decrease in tumour necrosis factor alpha (TNF-alpha) concentrations in the serum of patients (patients, 6.36+/-0.90 pg/ml; controls, 10.5+/-1.23 pg/ml; p<0,05). The levels of other cytokines such as IFN-gamma, IL-2, IL-13 and transforming growth factor beta, as well as soluble cell adhesion molecules lymphocyte function-associated antigen 3 and intercellular adhesion molecule 1, were not significantly different compared with controls. Levels of immunoglobulin G2 (IgG2) measured in the serum of WD patients were below normal in 24 of 29 patients and were even below the 95% confidence interval in 10 patients., Conclusion: Our data demonstrate a persistent defect of the cellular immune response with decreased serum concentrations of IL-12p40 and TNF-alpha and decreased IgG2 levels in a large group of WD patients. These data support as in vivo finding the results obtained in previous investigations with stimulated monocytes/lymphocytes. The isolated decrease in IL-12p40 may hint at possible defects in the IL-12/IFN-gamma promoter system.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.